These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

271 related articles for article (PubMed ID: 37632661)

  • 1. Personalized Cancer Monitoring Assay for the Detection of ctDNA in Patients with Solid Tumors.
    Zhao J; Reuther J; Scozzaro K; Hawley M; Metzger E; Emery M; Chen I; Barbosa M; Johnson L; O'Connor A; Washburn M; Hartje L; Reckase E; Johnson V; Zhang Y; Westheimer E; O'Callaghan W; Malani N; Chesh A; Moreau M; Daber R
    Mol Diagn Ther; 2023 Nov; 27(6):753-768. PubMed ID: 37632661
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Can a Liquid Biopsy Detect Circulating Tumor DNA With Low-passage Whole-genome Sequencing in Patients With a Sarcoma? A Pilot Evaluation.
    Anderson CJ; Yang H; Parsons J; Ahrens WA; Jagosky MH; Hsu JH; Patt JC; Kneisl JS; Steuerwald NM
    Clin Orthop Relat Res; 2024 Jun; ():. PubMed ID: 38905450
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Whole exome sequencing of cell-free DNA - A systematic review and Bayesian individual patient data meta-analysis.
    Bos MK; Angus L; Nasserinejad K; Jager A; Jansen MPHM; Martens JWM; Sleijfer S
    Cancer Treat Rev; 2020 Feb; 83():101951. PubMed ID: 31874446
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Strategies for improving detection of circulating tumor DNA using next generation sequencing.
    Tébar-Martínez R; Martín-Arana J; Gimeno-Valiente F; Tarazona N; Rentero-Garrido P; Cervantes A
    Cancer Treat Rev; 2023 Sep; 119():102595. PubMed ID: 37390697
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Analytical performance evaluation of a commercial next generation sequencing liquid biopsy platform using plasma ctDNA, reference standards, and synthetic serial dilution samples derived from normal plasma.
    Verma S; Moore MW; Ringler R; Ghosal A; Horvath K; Naef T; Anvari S; Cotter PD; Gunn S
    BMC Cancer; 2020 Oct; 20(1):945. PubMed ID: 33004033
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Variants with a low allele frequency detected in genomic DNA affect the accuracy of mutation detection in cell-free DNA by next-generation sequencing.
    Wang JF; Pu X; Zhang X; Chen K; Xi Y; Wang J; Mao X; Zhang J; Heymach JV; Antonoff MB; Hofstetter WL; Mehran RJ; Rice DC; Roth JA; Sepesi B; Swisher SG; Vaporciyan AA; Walsh GL; Meng QH; Shaw KR; Eterovic AK; Fang B
    Cancer; 2018 Mar; 124(5):1061-1069. PubMed ID: 29178133
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Somatic mutation detection using various targeted detection assays in paired samples of circulating tumor DNA, primary tumor and metastases from patients undergoing resection of colorectal liver metastases.
    Beije N; Helmijr JC; Weerts MJA; Beaufort CM; Wiggin M; Marziali A; Verhoef C; Sleijfer S; Jansen MPHM; Martens JWM
    Mol Oncol; 2016 Dec; 10(10):1575-1584. PubMed ID: 28949453
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High-Sensitivity Mutation Analysis of Cell-Free DNA for Disease Monitoring in Endometrial Cancer.
    Ashley CW; Selenica P; Patel J; Wu M; Nincevic J; Lakhman Y; Zhou Q; Shah RH; Berger MF; Da Cruz Paula A; Brown DN; Marra A; Iasonos A; Momeni-Boroujeni A; Alektiar KM; Long Roche K; Zivanovic O; Mueller JJ; Zamarin D; Broach VA; Sonoda Y; Leitao MM; Friedman CF; Jewell E; Reis-Filho JS; Ellenson LH; Aghajanian C; Abu-Rustum NR; Cadoo K; Weigelt B
    Clin Cancer Res; 2023 Jan; 29(2):410-421. PubMed ID: 36007103
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification of liquid biopsy-based mutations in colorectal cancer by targeted sequencing assays.
    Szász I; Kiss T; Mokánszki A; Koroknai V; Deák J; Patel V; Jámbor K; Ádány R; Balázs M
    Mol Cell Probes; 2023 Feb; 67():101888. PubMed ID: 36513244
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical significance of the mutational landscape and fragmentation of circulating tumor DNA in renal cell carcinoma.
    Yamamoto Y; Uemura M; Fujita M; Maejima K; Koh Y; Matsushita M; Nakano K; Hayashi Y; Wang C; Ishizuya Y; Kinouchi T; Hayashi T; Matsuzaki K; Jingushi K; Kato T; Kawashima A; Ujike T; Nagahara A; Fujita K; Imamura R; Nakagawa H; Nonomura N
    Cancer Sci; 2019 Feb; 110(2):617-628. PubMed ID: 30536551
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Enhanced detection of minimal residual disease by targeted sequencing of phased variants in circulating tumor DNA.
    Kurtz DM; Soo J; Co Ting Keh L; Alig S; Chabon JJ; Sworder BJ; Schultz A; Jin MC; Scherer F; Garofalo A; Macaulay CW; Hamilton EG; Chen B; Olsen M; Schroers-Martin JG; Craig AFM; Moding EJ; Esfahani MS; Liu CL; Dührsen U; Hüttmann A; Casasnovas RO; Westin JR; Roschewski M; Wilson WH; Gaidano G; Rossi D; Diehn M; Alizadeh AA
    Nat Biotechnol; 2021 Dec; 39(12):1537-1547. PubMed ID: 34294911
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Modeling clonal structure over narrow time frames via circulating tumor DNA in metastatic breast cancer.
    Weber ZT; Collier KA; Tallman D; Forman J; Shukla S; Asad S; Rhoades J; Freeman S; Parsons HA; Williams NO; Barroso-Sousa R; Stover EH; Mahdi H; Cibulskis C; Lennon NJ; Ha G; Adalsteinsson VA; Tolaney SM; Stover DG
    Genome Med; 2021 May; 13(1):89. PubMed ID: 34016182
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Individualized Mini-Panel Sequencing of ctDNA Allows Tumor Monitoring in Complex Karyotype Sarcomas.
    Braig D; Runkel A; Eisenhardt AE; Schmid A; Zeller J; Pauli T; Lausch U; Wehrle J; Bronsert P; Jung M; Kiefer J; Boerries M; Eisenhardt SU
    Int J Mol Sci; 2022 Sep; 23(18):. PubMed ID: 36142126
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Validation of ctDNA Quality Control Materials Through a Precompetitive Collaboration of the Foundation for the National Institutes of Health.
    Williams PM; Forbes T; P Lund S; Cole KD; He HJ; Karlovich C; Paweletz CP; Stetson D; Yee LM; Connors DE; Keating SM; Destenaves B; Cleveland MH; Lau CJ; Barrett JC; Kelloff GJ; McCormack RT
    JCO Precis Oncol; 2021; 5():. PubMed ID: 34250423
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Circulating tumour DNA sequencing to determine therapeutic response and identify tumour heterogeneity in patients with paediatric solid tumours.
    Stankunaite R; George SL; Gallagher L; Jamal S; Shaikh R; Yuan L; Hughes D; Proszek PZ; Carter P; Pietka G; Heide T; James C; Tari H; Lynn C; Jain N; Portela LR; Rogers T; Vaidya SJ; Chisholm JC; Carceller F; Szychot E; Mandeville H; Angelini P; Jesudason AB; Jackson M; Marshall LV; Gatz SA; Anderson J; Sottoriva A; Chesler L; Hubank M
    Eur J Cancer; 2022 Feb; 162():209-220. PubMed ID: 34933802
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Analytical Performance Evaluation of a 523-Gene Circulating Tumor DNA Assay for Next-Generation Sequencing-Based Comprehensive Tumor Profiling in Liquid Biopsy Samples.
    Harter J; Buth E; Johaenning J; Battke F; Kopp M; Zelba H; Schulze M; Koedding J; Biskup S
    J Mol Diagn; 2024 Jan; 26(1):61-72. PubMed ID: 37865292
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Somatic copy number alteration and fragmentation analysis in circulating tumor DNA for cancer screening and treatment monitoring in colorectal cancer patients.
    Hallermayr A; Wohlfrom T; Steinke-Lange V; Benet-Pagès A; Scharf F; Heitzer E; Mansmann U; Haberl C; de Wit M; Vogelsang H; Rentsch M; Holinski-Feder E; Pickl JMA
    J Hematol Oncol; 2022 Sep; 15(1):125. PubMed ID: 36056434
    [TBL] [Abstract][Full Text] [Related]  

  • 18. NGS-Based Tumor-Informed Analysis of Circulating Tumor DNA.
    Nordentoft I; Birkenkamp-Demtröder K; Dyrskjøt L
    Methods Mol Biol; 2023; 2684():179-197. PubMed ID: 37410235
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Next-generation sequencing for tumor mutation quantification using liquid biopsies.
    Provencio M; Pérez-Barrios C; Barquin M; Calvo V; Franco F; Sánchez E; Sánchez R; Marsden D; Cristóbal Sánchez J; Martin Acosta P; Laza-Briviesca R; Cruz-Bermúdez A; Romero A
    Clin Chem Lab Med; 2020 Jan; 58(2):306-313. PubMed ID: 31469650
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of tumor-informed and tumor-naïve sequencing assays for ctDNA detection in breast cancer.
    Santonja A; Cooper WN; Eldridge MD; Edwards PAW; Morris JA; Edwards AR; Zhao H; Heider K; Couturier DL; Vijayaraghavan A; Mennea P; Ditter EJ; Smith CG; Boursnell C; Manzano García R; Rueda OM; Beddowes E; Biggs H; Sammut SJ; Rosenfeld N; Caldas C; Abraham JE; Gale D
    EMBO Mol Med; 2023 Jun; 15(6):e16505. PubMed ID: 37161793
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.